Another study of triple-negative breast cancer by Humphries et al. showed that ARHGAP18 could function as the oncogene by blocking RhoA signaling and reversing the inhibition of miR-200b on cell migration [27]. This evidence concerns the gene ARHGAP18 and triple-negative breast carcinoma.